Noticias de SVRA_US

Noticias del mercado

Últimas noticias sobre SVRA_US — 201 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SVRA_US ✕ 201 resultados
16/04/2026 SVRA_US — BioSpace
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

16/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
16/04/2026 SVRA_US — Seeking Alpha
Savara gets FDA review extension for lead asset (SVRA:NASDAQ)
16/04/2026 SVRA_US — GuruFocus
Savara (SVRA) Receives FDA Review Extension for Molgramostim App
15/04/2026 SVRA_US — MSN
SVRA stock slips post-market after FDA delays decision on pulmonary therapy
15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
15/04/2026 SVRA_US — BioSpace
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
15/04/2026 SVRA_US — Yahoo Finance
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application
15/04/2026 SVRA_US — Stocktwits
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Savara Inc. (SVRA) estaba buscando luz verde de la FDA para molgramostim en la proteinosis alveolar pulmonar autoinmune.

15/04/2026 SVRA_US — ChartMill
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune…

15/04/2026 SVRA_US — Investing.com
FDA extends review of Savara’s molgramostim application By Investing.com
14/04/2026 SVRA_US — Investing.com
Savara to present molgramostim data at ATS conference in May By Investing.com
14/04/2026 SVRA_US — Investing.com
Savara to present molgramostim data at ATS conference in May By Investing.com
14/04/2026 SVRA_US — Yahoo Finance
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
14/04/2026 SVRA_US — Investing.com
Savara to present molgramostim data at ATS conference in May
14/04/2026 SVRA_US — Investing.com
Savara to present molgramostim data at ATS conference in May By Investing.com
14/04/2026 SVRA_US — Investing.com
Savara to present molgramostim data at ATS conference in May By Investing.com
14/04/2026 SVRA_US — The Joplin Globe
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
14/04/2026 SVRA_US — Business Wire
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Página 9 de 11

keyboard_arrow_up